Resources & Clinical Research
Results of clinical studies demonstrate that VAX-D is an effective treatment for the management of patients with chronic back pain.
An outcome study on 778 patients and a prospective randomized, controlled study both reported approximately 70% success rates and improvements in functional outcomes for patients suffering from disc-related chronic back pain.
In addition, several research articles have been published examining the mechanism of action of VAX-D. Studies on the effects of VAX-D on intradiscal pressures have been reported, and its effects on sensory nerve dysfunction in with low back pain and radiculopathy.
Studies that utilized CPT Neurometry and Dermatomal Somatosensory Evoked Potentials (DSSEP's) have demonstrated nerve decompression following VAX-D Therapy.
Study after study shows...
VAX-D Is Proven Effective
Don't Get Caught with False Advertising. Protect Your Livelihood.
Medical and chiropractic licensing bodies and the Office of The Attorney General are enforcing the law: "The law prohibits the promotion of health care services based upon anything less than scientifically substantiated claims. A scientific claim that cannot be substantiated by a reliable, peer reviewed, published scientific study is a false and deceptive advertisement. Advertisements referencing a study or clinical proof must be supported by valid clinical studies".
A recent two and one-half year study sponsored by Independence Blue Cross (Arch Phys Med Rehab Vol 89, February 2008) has also confirmed the effectiveness of VAX-D. The purpose of the study was to determine short- and long-term outcomes after VAX-D treatment in a large sample (296 subjects) of patients with activity-limiting low back pain that had failed at least two previous, non-surgical treatments. The study showed that patients had significantly improved pain and disability scores at end of treatment, at 30 days and at 180 days post-discharge.
Published Credibility: The textbook 'The Practice of Minimally Invasive Spinal Technique - 2005 Edition' (published by the American College of Physicians and The American Academy of Minimally Invasive Spinal Medicine & Surgery) has now devoted an entire chapter to VAX-D treatment. The textbook states "VAX-D should not be considered traction in the traditional sense but as decompression. VAX-D is the only non-invasive treatment that has been proven to decompress the disc."
Patient Study: VAX-D was successful in 71% of the 778 cases. "The pain, activity and mobility scores were all greatly improved after therapy. VAX-D by its unique design may more precisely address the physiology of persistent low back pain than other therapies. We consider it to be a front-line treatment for back pain, and post-surgical patients with persistent pain or 'Failed Back Syndrome' should not be considered candidates for further surgery until a trial of VAX-D has been tried".